Prev: Historical Perspective on Antinuclear Antibody TestingNext: Prescription medication use and antinuclear antibodies in the United States, 1999-2004
Record 061 · Review · 2022
67%22.61.X
Antinuclear Antibody Testing: Gold Standard Revisited
The Journal of Applied Laboratory Medicine · requested inclusion
“Reviews HEp-2 immunofluorescence, nomenclature, interpretation, and unresolved standardization issues.”
Reviews HEp-2 immunofluorescence, nomenclature, interpretation, and unresolved standardization issues. Limits noted in the record: Review mixes established findings with proposals for future reporting. A positive ANA is not a diagnosis. Claims in this record are not verified.
A positive ANA is not a diagnosis. Claims in this record are not verified.
source
- testing-method
- pattern
- prevalence
Review
Also in this file
View all in file
Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications00.44.X · Review article
Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective19.45.X · Annals of the Rheumatic Diseases
The Art of Interpreting Antinuclear Antibodies (ANAs) in Everyday Practice25.46.X · Journal of Clinical Medicine (MDPI)
The International Consensus on ANA Patterns (ICAP) in 2021—The 6th Workshop and Current Perspectives22.47.X · Journal of Applied Laboratory Medicine